These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38133557)

  • 1. Serum CXCL10 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced BCLC stage C hepatocellular carcinoma: A multicenter analysis.
    Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Matoya S; Miyaki T; Kimura Y; Kusakabe A; Narahara S; Tokunaga T; Nagaoka K; Kuroyanagi K; Kawamura H; Kuno K; Fujiwara K; Nojiri S; Kataoka H; Tanaka Y
    Cancer Med; 2024 Jan; 13(1):e6876. PubMed ID: 38133557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Nutritional Index after Introduction of Atezolizumab with Bevacizumab Predicts Prognosis in Advanced Hepatocellular Carcinoma: A Multicenter Study.
    Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Kato D; Kusakabe A; Koguchi H; Hasegawa I; Matoya S; Miyaki T; Kimura Y; Tanaka Y; Kondo H; Ozasa A; Kawamura H; Kuno K; Fujiwara K; Nojiri S; Kataoka H;
    Oncology; 2024; 102(8):676-687. PubMed ID: 38237558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.
    Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Matoya S; Miyaki T; Kimura Y; Kusakabe A; Narahara S; Tokunaga T; Nagaoka K; Murakami S; Inoue T; Kuroyanagi K; Kawamura H; Fujiwara K; Nojiri S; Kataoka H; Tanaka Y
    J Gastroenterol Hepatol; 2024 Jun; ():. PubMed ID: 38943340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kudo M;
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1464. PubMed ID: 34114752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Similar Efficacy Between Atezolizumab Plus Bevacizumab
    Kuwano A; Yada M; Tanaka K; Koga Y; Nagasawa S; Masumoto A; Motomura K
    In Vivo; 2024; 38(4):1854-1858. PubMed ID: 38936922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab.
    Kikuchi T; Takeuchi Y; Nouso K; Kariyama K; Kuwaki K; Toshimori J; Iwado S; Moriya A; Hagihara H; Takabatake H; Tada T; Yasunaka T; Sakata M; Sue M; Miyake N; Adachi T; Wada N; Onishi H; Shiraha H; Takaki A; Otsuka M
    Liver Int; 2024 Jun; 44(6):1456-1463. PubMed ID: 38488749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma.
    Song BG; Goh MJ; Kang W; Sinn DH; Gwak GY; Choi MS; Lee JH; Paik YH
    Gut Liver; 2024 Jul; 18(4):709-718. PubMed ID: 38932499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel concept of "sequential particle radiotherapy" with atezolizumab plus bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus.
    Komatsu S; Terashima K; Ishihara N; Matsuo Y; Kido M; Yanagimoto H; Toyama H; Tokumaru S; Okimoto T; Fukumoto T
    Surg Today; 2024 Aug; 54(8):972-976. PubMed ID: 38436718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
    Tajiri K; Tsukada K; Tokimitsu Y; Motofuji Y; Kawai K; Muraishi N; Murayama A; Hayashi Y; Shimizu Y; Yasuda I
    Oncology; 2024; 102(2):131-140. PubMed ID: 37666216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study).
    Kobayashi K; Ogasawara S; Itobayashi E; Okubo T; Itokawa N; Nakamura K; Moriguchi M; Watanabe S; Ikeda M; Kuroda H; Kawaoka T; Hiraoka A; Yasui Y; Kuzuya T; Sato R; Kanzaki H; Koroki K; Inoue M; Nakamura M; Kiyono S; Kanogawa N; Kondo T; Nakamoto S; Ozawa Y; Tsuchiya K; Atsukawa M; Aikata H; Aramaki T; Oka S; Morimoto N; Kurosaki M; Itoh Y; Izumi N; Kato N
    Invest New Drugs; 2024 Aug; 42(4):394-404. PubMed ID: 38842657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
    Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.
    Kobayashi S; Fukushima T; Ueno M; Chuma M; Numata K; Tsuruya K; Arase Y; Hirose S; Kagawa T; Hattori N; Watanabe T; Matsunaga K; Uojima H; Hidaka H; Kusano C; Morimoto M; Maeda S
    Liver Int; 2024 Jun; 44(6):1343-1350. PubMed ID: 38436529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neutrophil-to-lymphocyte ratio at the start of the second course during atezolizumab plus bevacizumab therapy predicts therapeutic efficacy in patients with advanced hepatocellular carcinoma: A multicenter analysis.
    Matoya S; Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Kuroyanagi K; Kusakabe A; Koguchi H; Hasegawa I; Miyaki T; Tanaka Y; Kondo H; Kimura Y; Ozasa A; Kawamura H; Kuno K; Fujiwara K; Nojiri S; Kataoka H;
    Hepatol Res; 2023 Jun; 53(6):511-521. PubMed ID: 36723964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Atezolizumab Plus Bevacizumab Versus Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma: a Meta-analysis.
    Changez MIK; Khan M; Uzair M; Tahir MF; Mohsin M; Hussain AF; Saqib V; Molani MK; Ahmed AH; Khalid S
    J Gastrointest Cancer; 2024 Mar; 55(1):467-481. PubMed ID: 38095799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    Shimose S; Iwamoto H; Shirono T; Tanaka M; Niizeki T; Kajiwara M; Itano S; Yano Y; Matsugaki S; Moriyama E; Noda Y; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
    Cancer Med; 2023 Jun; 12(11):12325-12335. PubMed ID: 37062077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.
    Yamaba S; Imai Y; Sugawara K; Uchida Y; Fuchigami A; Uchiya H; Nakayama N; Mochida S
    PLoS One; 2024; 19(4):e0298770. PubMed ID: 38687817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma.
    Kuzuya T; Kawabe N; Hashimoto S; Miyahara R; Sawaki A; Nakano T; Nakaoka K; Tanaka H; Miyachi Y; Mii A; Kamejima S; Takahara T; Kato Y; Sugioka A; Hirooka Y
    Oncology; 2022; 100(1):12-21. PubMed ID: 34731863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study.
    Chon YE; Kim DY; Kim MN; Kim BK; Kim SU; Park JY; Ahn SH; Ha Y; Lee JH; Lee KS; Kang B; Kim JS; Chon HJ; Kim DY
    Clin Mol Hepatol; 2024 Jul; 30(3):345-359. PubMed ID: 38468561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
    Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
    Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.